European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay

J Clin Microbiol. 2017 Apr;55(4):1186-1192. doi: 10.1128/JCM.02163-16. Epub 2017 Feb 1.

Abstract

The analytical performance of the Veris HCV Assay for use on the new and fully automated Beckman Coulter DxN Veris Molecular Diagnostics System (DxN Veris System) was evaluated at 10 European virology laboratories. Precision, analytical sensitivity, specificity, and performance with negative samples, linearity, and performance with hepatitis C virus (HCV) genotypes were evaluated. Precision for all sites showed a standard deviation (SD) of 0.22 log10 IU/ml or lower for each level tested. Analytical sensitivity determined by probit analysis was between 6.2 and 9.0 IU/ml. Specificity on 94 unique patient samples was 100%, and performance with 1,089 negative samples demonstrated 100% not-detected results. Linearity using patient samples was shown from 1.34 to 6.94 log10 IU/ml. The assay demonstrated linearity upon dilution with all HCV genotypes. The Veris HCV Assay demonstrated an analytical performance comparable to that of currently marketed HCV assays when tested across multiple European sites.

Keywords: HCV; analytical performance; automated; quantitation.

Publication types

  • Evaluation Study
  • Multicenter Study

MeSH terms

  • Automation, Laboratory / methods*
  • Europe
  • Hepacivirus / isolation & purification*
  • Hepatitis C, Chronic / virology*
  • Humans
  • Real-Time Polymerase Chain Reaction / methods*
  • Sensitivity and Specificity
  • Viral Load / methods*